BR9806413A - Composto e uso do mesmo - Google Patents

Composto e uso do mesmo

Info

Publication number
BR9806413A
BR9806413A BR9806413-4A BR9806413A BR9806413A BR 9806413 A BR9806413 A BR 9806413A BR 9806413 A BR9806413 A BR 9806413A BR 9806413 A BR9806413 A BR 9806413A
Authority
BR
Brazil
Prior art keywords
con
group
formula
substituents
alkyl
Prior art date
Application number
BR9806413-4A
Other languages
English (en)
Inventor
Takashi Fujita
Tomishisa Yokoyama
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR9806413A publication Critical patent/BR9806413A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTO E USO DO MESMO". Compostos da fórmula (I): [em que: um de m e n é 0, e o outro é 0, 1 ou 2; k é 0 ou um número inteiro de 1 a 12; R^ 1^ é hidrogênio, um dos substituintes <244>, definidos abaixo, ou um grupo alquila opcionalmente substituído; A é uma ligação única, um átomo de oxigênio, um grupo carbonila ou um grupo da fórmula -N (R^ 2^) CO-, -N (R^ 2^) CS-, -N (R^ 2^) SO~ 2~-, -CON (R^ 2^) N (R^ 3^) CO-, -CON (R^ 2^) CO-, -CON (R^ 2^) CS-, -CON (R^ 2^) SO~ 2~-, -O-CO-, -ON (R^ 2^) CO-, -ON (R^ 2^) SO~ 2~-, -O-CON (R^ 2^), N (R^ 3^) CO-, -O-CON (R^ 2^) CO-, -O-CON (R^ 2^) SO~ 2~-, -CO-O-, -CO-CO-, -CO-CON (R^ 2^) N (R^ 3^) CO-, -CO-CON (R^ 2^) CO-, -CO-CON (R^ 2^) SO~ 2~-, -N (R^ 2^) O-, -N (R^ 2^) COCO-, -N (R^ 2^) N (R^ 3^) CO-, -N (R^ 2^) N (R^ 3^) SO~ 2~-, -N (R^ 2^) CON (R^ 3^) N (R^ 4^) CO-, -N (R^ 2^) CON (R^ 3^) CO-, -N (R^ 2^) CON (R^ 3^) SO~ 2~ ou -N (R^ 2^) CON (R^ 3^) SO~ 2~N (R^ 4^) CO- em que R^ 2^, R^ 3^ e R^ 4^ são iguais ou diferentes e cada é hidrogênio, alquila, aralquila, acila ou um dos substituintes <244>; B é uma ligação única, ou um grupo da fórmula -N (R^ 5^)- ou N (R^ 6^) N (R^ 5^)- em que R^ 5^ e R^ 6^ são iguais ou diferentes e cada é hidrogênio, alquila, aralquila, acila ou um dos substituintes <244>, ou R^ 5^, junto com R^ 1^ e o átomo de nitrogênio para que eles são ligados, podem formar um anel heterocíclico dentre 5 a 7 átomos de anéis; ou R^ 1^ pode representar um grupo da fórmula -OR^ 7^, em que R^ 7^ é alquila, alquenila, aralquila ou um dos substituintes <244>; ou R^ 1^ pode representar um grupo hidroxi ou um grupo da fórmula -OR^ 7^; e os referidos substituintes a são selecionados dentre os grupos arila e grupos heterocíclico] e sais farmaceuticamente aceitáveis dos mesmos tendo uma habilidade excelente para melhorar a atividade de reductase de glutationa e podem assim ser usados para o tratamento e prevenção de uma variedade de doenças incluindo cataratas.
BR9806413-4A 1997-04-02 1998-04-02 Composto e uso do mesmo BR9806413A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8374997 1997-04-02
JP883798 1998-01-20

Publications (1)

Publication Number Publication Date
BR9806413A true BR9806413A (pt) 2003-04-15

Family

ID=26343433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806413-4A BR9806413A (pt) 1997-04-02 1998-04-02 Composto e uso do mesmo

Country Status (24)

Country Link
US (2) US6013663A (pt)
EP (2) EP1070710A3 (pt)
KR (1) KR19980081044A (pt)
CN (1) CN1208035A (pt)
AR (1) AR012315A1 (pt)
AT (1) ATE221525T1 (pt)
AU (1) AU728488B2 (pt)
BR (1) BR9806413A (pt)
CA (1) CA2233682A1 (pt)
CZ (1) CZ96798A3 (pt)
DE (1) DE69806831T2 (pt)
DK (1) DK0869126T3 (pt)
ES (1) ES2179427T3 (pt)
HK (1) HK1015765A1 (pt)
HU (1) HUP9800743A3 (pt)
ID (1) ID19824A (pt)
IL (1) IL123887A0 (pt)
NO (1) NO981469L (pt)
NZ (1) NZ330092A (pt)
PL (1) PL325691A1 (pt)
PT (1) PT869126E (pt)
RU (2) RU2165932C2 (pt)
TR (2) TR199800602A3 (pt)
TW (1) TW508354B (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090842A (en) * 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
WO2000007582A2 (en) * 1998-08-06 2000-02-17 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
EP1486495B1 (en) 1998-10-26 2009-12-09 The Research Foundation of State University of New York Salts of lipoic acid derivatives and their use in treatment of disease
WO2000031060A1 (en) 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Scavenger compounds
FR2787109B1 (fr) * 1998-12-15 2001-01-19 Adir Nouveaux derives de 1,2-dithiolane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
FR2791677B1 (fr) * 1999-04-02 2001-08-17 Sod Conseils Rech Applic Nouveaux derives de l'acide lipoique, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
FR2805537A1 (fr) * 2000-02-24 2001-08-31 Sod Conseils Rech Applic Nouveaux derives de l'acide lipoique, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
IT1312569B1 (it) * 1999-05-21 2002-04-22 Raffaele Ansovini Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
GB9913226D0 (en) * 1999-06-07 1999-08-04 Novartis Ag Organic compounds
DE19941217A1 (de) * 1999-08-30 2001-03-15 Asta Medica Ag Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
WO2001025226A1 (en) * 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1265891B1 (fr) * 2000-03-16 2004-12-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives heterocycliques ou benzeniques de l'acide lipoique, leur preparation et leur application a titre de medicaments
FR2806409B1 (fr) * 2000-03-16 2002-04-19 Sod Conseils Rech Applic Nouveaux derives heterocycliques de l'acide lipoique, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US6495170B1 (en) * 2000-08-16 2002-12-17 N. V. Nutricia Method of increasing the presence of glutathione in cells
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
IT1319195B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Processo per la produzione dell'acido r(+)alfa-lipoico.
IT1319196B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
DE10201464B4 (de) * 2002-01-16 2005-06-16 Viatris Gmbh & Co. Kg Verfahren zur Herstellung reiner Thioctsäure
AU2003219880A1 (en) * 2002-02-22 2003-09-09 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
WO2003074510A1 (de) * 2002-03-05 2003-09-12 Universitaet Ulm Dithiolan-derivate zur immobilisierung von biomolekülen auf edelmetallen und halbleitern
JP3970811B2 (ja) 2002-09-09 2007-09-05 独立行政法人科学技術振興機構 リンカー化合物及びリガンド、並びにそれらの製造方法
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
US7202270B2 (en) * 2003-06-20 2007-04-10 Sami Labs Limited Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses
US7462526B2 (en) * 2003-11-18 2008-12-09 Silicon Genesis Corporation Method for fabricating semiconductor devices using strained silicon bearing material
US20080102119A1 (en) * 2006-11-01 2008-05-01 Medtronic, Inc. Osmotic pump apparatus and associated methods
US7389347B2 (en) * 2004-04-16 2008-06-17 International Business Machines Corporation Active probing for real-time diagnosis
EA200701584A1 (ru) 2005-01-27 2008-02-28 Альма Матер Студиорум - Университа' Ди Болонья Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
US8178083B2 (en) * 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
CN100436444C (zh) * 2006-07-29 2008-11-26 常熟富士莱医药化工有限公司 硫辛酰胺合成工艺
CA2591496C (en) 2006-12-18 2014-09-02 Japan Science And Technology Agency Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods
JP2010520333A (ja) * 2007-03-01 2010-06-10 セダーズ−シナイ メディカル センター 〔１，２〕−ジチオラン部分を含有する抗酸化剤重合体およびその使用
KR101056037B1 (ko) * 2007-07-20 2011-08-10 (주)바이오제닉스 알파-리포일기 함유 아스코르브산 유도체 및 그의 제조방법
WO2009014343A2 (en) * 2007-07-20 2009-01-29 Biogenics, Inc. Ascorbic acid derivatives having alpha-lipoyl groups and process for preparing the same
KR101056039B1 (ko) * 2007-07-20 2011-08-10 (주)바이오제닉스 알파-리포일기 함유 아스코르브산 유도체 및 그의 제조방법
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
US8102027B2 (en) * 2007-08-21 2012-01-24 Broadcom Corporation IC package sacrificial structures for crack propagation confinement
US9028874B2 (en) * 2008-01-03 2015-05-12 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
CN101497600B (zh) * 2008-01-29 2012-02-08 首都医科大学 2,4,5-三取代-1,3-二硫戊环、其合成方法、其应用
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
CN103251631A (zh) * 2008-05-13 2013-08-21 根梅迪卡治疗公司 用于治疗代谢性病症的水杨酸盐(酯)缀合物
US8603531B2 (en) * 2008-06-02 2013-12-10 Cedars-Sinai Medical Center Nanometer-sized prodrugs of NSAIDs
FR2936153B1 (fr) * 2008-09-24 2010-10-08 Oreal Utilisations de composes dithiolanes pour la photoprotection de la peau ; nouveaux composes dithiolanes ; compositions les contenant.
FR2936146B1 (fr) * 2008-09-24 2010-10-08 Oreal Utilisations de composes dithiolanes pour la photoprotection de la peau ; nouveaux composes dithiolanes ; compositions les contenant.
FR2936706B1 (fr) * 2008-10-08 2010-12-17 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
FR2937035B1 (fr) * 2008-10-10 2010-12-31 Oreal Composes dithiolanes ; compositions les contenant ; utilisations pour la photoprotection de la peau
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
FR2939042B1 (fr) 2008-11-28 2010-11-26 Oreal PROCEDE DE DEPIGMENTATION DES MATIERES KERATINIQUES A l'AIDE DE COMPOSES DITHIOLANNES.
CN101787013B (zh) * 2009-01-22 2013-04-24 杭州民生药业有限公司 硫辛酰胺系列衍生物、制备方法及所述衍生物的制药用途
AU2010224867A1 (en) * 2009-03-16 2011-10-06 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders
EP2408443A1 (en) * 2009-03-16 2012-01-25 Genmedica Therapeutics SL Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
US8410162B2 (en) 2009-06-15 2013-04-02 Encore Health Llc Choline esters
DK2442647T3 (en) 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivatives thereof, and the uses of these
FR2952300B1 (fr) * 2009-11-09 2012-05-11 Oreal Nouveaux colorants fluorescents a motif heterocyclique disulfure, composition de teinture les comprenant et procede de coloration des fibres keratiniques humaines a partir de ces colorants
EP2640423B1 (en) * 2010-11-18 2017-07-26 Ischemix LLC Lipoyl compounds and their use for treating ischemic injury
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
JP6480340B2 (ja) 2012-11-15 2019-03-06 ブランデイズ ユニバーシティー 環状ジスルフィドを用いるシステイン残基のテザリング
EP3110800A1 (en) * 2014-02-27 2017-01-04 Consorzio Interuniversitario Nazionale Per La Scienza E La Tecnologia Dei Materiali (INSTM) Novel compounds having anti-allodynic and antihyperalgesic activity
RU2735790C2 (ru) 2014-03-03 2020-11-09 Энкор Вижн, Инк. Композиции и способы применения холинового эфира липоевой кислоты
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2017031226A1 (en) 2015-08-18 2017-02-23 Brandeis University Tethering cysteine residues using cyclic disulfides
ES2906178T3 (es) * 2016-03-14 2022-04-13 Neostrata Company Inc Aminoácido o péptido N-lipoico, derivados y sus usos
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN106866620B (zh) * 2017-03-30 2019-09-20 山东齐都药业有限公司 一种硫辛酸氧化杂质的制备方法
JP7203756B2 (ja) 2017-04-25 2023-01-13 イスケミックス エルエルシー 外傷性脳傷害を治療するための組成物および方法
CA3136938A1 (en) * 2019-04-17 2020-10-22 Santen Pharmaceutical Co., Ltd. Lipoic acid prodrug
CN110294738A (zh) * 2019-07-22 2019-10-01 通化师范学院 硫辛酸衍生物及其制备方法和用途
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1210892B (de) * 1959-10-13 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung von 5[3-(1, 2-Dithiacylopentyl)]-pentan-saeureamiden
DE1210893B (de) * 1960-06-17 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung von 6, 8-Dithiooctansaeureamiden
FR1294134A (fr) * 1960-12-27 1962-05-26 Takeda Pharmaceutical Ind Procédé de préparation d'alpha-lipoamides
CH656382A5 (de) * 1983-10-24 1986-06-30 Sandoz Ag Sulfoxide, verfahren zu ihrer herstellung und ihre verwendung.
JPH0673005B2 (ja) * 1985-01-24 1994-09-14 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
JPH0670133B2 (ja) * 1985-08-29 1994-09-07 出光興産株式会社 リポアミド膜およびその製造法
JP2553090B2 (ja) 1987-07-21 1996-11-13 帝人株式会社 組織グルタチオンレベル向上剤
FR2653334B1 (fr) * 1989-10-19 1991-12-20 Erphar Ste Civile Preparation cosmetique de bronzage.
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
IT1252865B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
IT1256178B (it) 1992-11-30 1995-11-29 Lorenzo Ferrari Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
FR2707983A1 (fr) * 1993-07-21 1995-01-27 Pf Medicament Nouveaux dérivés de l'acide lipoïque et dihydrolipoïque, leur préparation et leur application en thérapeutique humaine.
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
DE69620233T2 (de) * 1995-12-14 2002-11-14 Novelos Therapeutics Inc Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren

Also Published As

Publication number Publication date
DK0869126T3 (da) 2002-11-18
KR19980081044A (ko) 1998-11-25
DE69806831D1 (de) 2002-09-05
NO981469D0 (no) 1998-04-01
RU99119545A (ru) 2004-03-27
ATE221525T1 (de) 2002-08-15
TR200202678A2 (tr) 2004-01-21
HU9800743D0 (en) 1998-05-28
EP0869126A1 (en) 1998-10-07
TR199800602A2 (xx) 1999-10-21
US6313164B1 (en) 2001-11-06
NO981469L (no) 1998-10-05
PT869126E (pt) 2002-10-31
AU728488B2 (en) 2001-01-11
EP1070710A3 (en) 2001-03-21
RU2169731C2 (ru) 2001-06-27
RU2165932C2 (ru) 2001-04-27
PL325691A1 (en) 1998-10-12
EP0869126B1 (en) 2002-07-31
TW508354B (en) 2002-11-01
AU5970298A (en) 1998-10-08
IL123887A0 (en) 1998-10-30
CN1208035A (zh) 1999-02-17
CA2233682A1 (en) 1998-10-02
DE69806831T2 (de) 2003-03-27
CZ96798A3 (cs) 1998-10-14
US6013663A (en) 2000-01-11
TR199800602A3 (tr) 1999-10-21
HUP9800743A3 (en) 2001-10-29
ID19824A (id) 1998-08-06
AR012315A1 (es) 2000-10-18
ES2179427T3 (es) 2003-01-16
EP1070710A2 (en) 2001-01-24
NZ330092A (en) 1999-04-29
MX9802679A (es) 1998-12-31
HUP9800743A2 (hu) 2000-05-28
HK1015765A1 (en) 1999-10-22

Similar Documents

Publication Publication Date Title
BR9806413A (pt) Composto e uso do mesmo
NO20014928L (no) Farmasöytiske forbindelser
BR0112484A (pt) Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
TR199800720T2 (xx) Farnesil transferaz inhibe eden 2-kinolon t�revleri.
BR0110404A (pt) Derivados de imidazopirimidina e derivados de triazolpirimidina
HUP9903766A2 (en) Pyridyl alkene- and pyridyl alkine- acid amides, use of them as cytostatics and immunosuppressives, process for their preparation and pharmaceuticals containing the same
BR0306811A (pt) Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
BR9807339A (pt) Derivados 3-piperidil-4-oxoquinazolina e composições farmacêuticas compreendendo os mesmos.
DE60005501D1 (de) 4&#39;-c-ethynyl-pyrimidine nukleoside
DE69507293T2 (de) Benzamid-derivate als vasopressin-antagonisten
HUP9801356A2 (hu) Triciklusos (2-hidroxi-2-metil-3,3,3-trifluor-propanoil)-amino-benzoxepin-, -benzotiepin-, -benzocikloheptén-, -indén-származékok és az ezeket tartalmazó gyógyszerkészítmények
ATE10804T1 (de) Ein diphenylhydantoin-derivat enthaltende pharmazeutische zusammensetzung, verwendete derivate und ihre herstellung.
BR9812922A (pt) Isoquinolinas como inibidores de uroquinase
BR0311410A (pt) Composto de piperidina
EA199801028A1 (ru) Применение производных п-аминофенола для проготовления фармацевтических композиций, используемых при лечении нейродегенеративных заболеваний
BR0212716A (pt) Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
BR0004534A (pt) Composto, composição farmacêutica, agente contendo um composto, e uso de um composto.
NO308532B1 (no) Farmasøytiske piperazinforbindelser
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5&lt;alfa&gt;-reduktaseinhibitorer
HUP9904594A2 (hu) Piperazinoszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR0214488A (pt) Derivados de benzotiazol
HUP9800146A2 (hu) Thalidomidszármazékok, eljárás előállításukra és felhasználásuk
BRPI9911178B8 (pt) derivados de 3-(2-oxo-[1,3&#39;]bipirrolidinil-3-ilidenometil)-cefems, bem como preparação farmacêutica e uso dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1855 DE 25/07/2006.